Advances in the research of nanodrug delivery system for targeted treatment of liver fibrosis
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Liver fibrosis is one of the major threats to human health. At present, anti-liver fibrosis drugs exist some problems,such as, lack of targeting, limited treatment effect and more or less toxic side effects. In order to improve the efficacy of targeted therapy for liver fibrosis, the development of a large number of nanocarriers and strategies of targeted therapy for liver fibrosis have been widely studied. In this paper, the research progress of nano-delivery vectors targeting cells related to the process of liver fibrosis in recent years was reviewed in terms of targeting vectors and the types of modified ligands, providing a new strategy for targeted cell therapy and theoretical reference for the realization of high efficient targeted therapy of liver fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Macrophage heterogeneity in liver injury and fibrosis
Tacke, F., & Zimmermann, H. W. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.12.025 · Cited by 1,061
Andrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ
Iredale, J. P. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30542 · Cited by 866
Origin of myofibroblasts in the fibrotic liver in mice
Iwaisako, K., Jiang, C., Zhang, M., Cong, M., Moore-Morris, T. J., Park, T. J., Liu, X., Xu, J., Wang, P., Paik, Y.-H., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1400062111 · Cited by 535
Liver sinusoidal endothelial cells in hepatic fibrosis
DeLeve, L. D. (2015) · Hepatology · doi:10.1002/hep.27376 · Cited by 482
Mesenchymal stem cells in fibrotic disease
El Agha, E., Kramann, R., Schneider, R. K., Li, X., Seeger, W., Humphreys, B. D., & Bellusci, S. (2017) · Cell stem cell · doi:10.1016/j.stem.2017.07.011 · Cited by 430
Bartneck, M., Scheyda, K. M., Warzecha, K. T., Rizzo, L. Y., Hittatiya, K., Luedde, T., Storm, G., Trautwein, C., Lammers, T., & Tacke, F. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.10.030 · Cited by 141
Cited by
Liver fibrosis resolution: from molecular mechanisms to therapeutic opportunities
Pei, Q., Yi, Q., & Tang, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119671 · Cited by 121
“However, the biodegradability of inorganic NPs in vivo is poor, and the leftover NPs that accumulate there can harm the liver.”
BackgroundInfluentialThe Role of Macrophages in Liver Fibrosis: New Therapeutic Opportunities
Binatti, E., Gerussi, A., Barisani, D., & Invernizzi, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126649 · Cited by 62
“Activated HSCs acquire a myofibroblast-like phenotype, proliferative, and migratory properties, and secrete large amount of ECM components in the Space of Disse [57].”
BackgroundInfluentialJia, H., Ding, L., Yu, A., Tang, W., Tang, S., Zhang, C., & Oupický, D. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.07.018 · Cited by 12
Macrophage heterogeneity in liver fibrosis
Wang, W., Li, S., Liu, Y., Ding, X., Yang, Y., Chen, S., Cao, J., Tacke, F., Dong, W., & Lan, T. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1639455 · Cited by 8
“This approach holds signi fi cant promise for the treatment of liver fi brosis (196).”
Self-citation
Metadata
- Authors
- Peng, W., Cheng, S., Bao, Z., Wang, Y., Zhou, W., Wang, J., Yang, Q., Chen, C., & Wang, W.
- Venue
- Biomedicine & Pharmacotherapy
- Publisher
- Elsevier BV
- Published
- 2021-05
- Volume
- 137
- Pages
- 111342
- ISSN
- 0753-3322 (ISSN-L)
- OpenAlex
- W3132621190
- Cited by
- 45
- References
- 7
- FWCI
- 1.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advances in the research of nanodrug delivery system for targeted treatment of liver fibrosis. https://app.cochat.ai/papers/10.1016/j.biopha.2021.111342
- The paper
- Peng, W., Cheng, S., Bao, Z., Wang, Y., Zhou, W., Wang, J., Yang, Q., Chen, C., & Wang, W. (2021). Advances in the research of nanodrug delivery system for targeted treatment of liver fibrosis. Biomedicine & Pharmacotherapy. https://doi.org/10.1016/j.biopha.2021.111342
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.